Figure 1 also shows that nebulized Budesonide (7.5 mg/mL, 30 min) failed to inhibit AHR under conditions where AuNPs (0.4 e 4 μg/mL, 30 min) were active. It is noteworthy that despite being unable to alter AHR caused to allergen exposure in this long-term asthma model, Budesonide did inhibit this response in mice subjected to a shorter-term version of it (only 4 instead of 9 weeks of allergen provocations) (Figure S1 in the online Supplementary Material). The gene discussed is AHR; the disease is asthma.